Sight Sciences, Inc. (NASDAQ:SGHT) Shares Bought by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. increased its stake in Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 27.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 410,325 shares of the company's stock after purchasing an additional 88,738 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.81% of Sight Sciences worth $1,494,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new position in shares of Sight Sciences during the 4th quarter worth $40,000. Arkadios Wealth Advisors acquired a new position in Sight Sciences during the fourth quarter worth about $47,000. WealthTrust Asset Management LLC acquired a new stake in shares of Sight Sciences in the fourth quarter valued at approximately $48,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Sight Sciences in the fourth quarter valued at approximately $50,000. Finally, Stoneridge Investment Partners LLC purchased a new position in shares of Sight Sciences during the 4th quarter worth approximately $55,000. Hedge funds and other institutional investors own 55.51% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on SGHT shares. Citigroup restated a "neutral" rating and issued a $3.60 price objective (up from $3.20) on shares of Sight Sciences in a research report on Thursday, May 22nd. Stifel Nicolaus decreased their price target on shares of Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Piper Sandler lowered their price target on shares of Sight Sciences from $5.50 to $3.50 and set a "neutral" rating for the company in a report on Thursday, March 6th. Lake Street Capital upped their price objective on shares of Sight Sciences from $2.50 to $3.00 and gave the company a "hold" rating in a research note on Friday, May 9th. Finally, UBS Group lowered their target price on shares of Sight Sciences from $5.50 to $5.00 and set a "buy" rating for the company in a research note on Monday, January 27th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $4.02.

Sight Sciences Trading Up 7.8%

SGHT stock traded up $0.25 on Tuesday, hitting $3.45. 95,709 shares of the company were exchanged, compared to its average volume of 230,889. The stock has a market capitalization of $178.35 million, a price-to-earnings ratio of -3.38 and a beta of 2.41. The business's fifty day moving average is $2.83 and its two-hundred day moving average is $3.09. Sight Sciences, Inc. has a twelve month low of $2.03 and a twelve month high of $8.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. The firm had revenue of $17.51 million for the quarter, compared to analysts' expectations of $16.51 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. As a group, research analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Manohar K. Raheja bought 10,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was bought at an average price of $2.73 per share, with a total value of $27,300.00. Following the completion of the transaction, the executive vice president now directly owns 145,000 shares of the company's stock, valued at approximately $395,850. This represents a 7.41% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul Badawi sold 24,174 shares of the firm's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the sale, the chief executive officer now owns 6,010,580 shares in the company, valued at approximately $13,824,334. The trade was a 0.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 35,196 shares of company stock worth $81,001 over the last ninety days. 30.90% of the stock is owned by company insiders.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.